Chr t(8;21) + KIT mutation
|
AML
|
Chr t(8;21) + KIT mutation
|
AML
|
venetoclax + midostaurin Sensitive: C3 – Early Trials
|
venetoclax + midostaurin Sensitive: C3 – Early Trials
|
Chr t(8;21) + KIT mutation
|
AML
|
Chr t(8;21) + KIT mutation
|
AML
|
venetoclax Resistant: C3 – Early Trials
|
venetoclax Resistant: C3 – Early Trials
|
Chr t(8;21) + KIT mutation
|
AML
|
Chr t(8;21) + KIT mutation
|
AML
|
cabozantinib tablet Sensitive: D – Preclinical
|
cabozantinib tablet Sensitive: D – Preclinical
|